- Double Mastectomy May Offer No Survival Benefit to Women With Breast Cancer
- Toxic Lead Found in Cinnamon Product, FDA Says
- Certain Abbott Blood Sugar Monitors May Give Incorrect Readings
- Athletes Can Expect High Ozone, Pollen Counts for Paris Olympics
- Fake Oxycontin Pills Widespread and Potentially Deadly: Report
- Shingles Vaccine Could Lower Dementia Risk
- Your Odds for Accidental Gun Death Rise Greatly in Certain States
- Kids From Poorer Families Less Likely to Survive Cancer
- Tough Workouts Won’t Trigger Cardiac Arrest in Folks With Long QT Syndrome
- At-Home Colon Cancer Test Can Save Lives
Jakafi Approved for Chronic Bone Marrow Disease
![](https://ladylively.com/wp-content/uploads/2013/08/blood1-300x336.jpg)
Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow.
Jakafi is the first FDA-sanctioned drug for the disease, which occurs when too many red blood cells are produced in the bone marrow. This may lead to a swollen spleen and phlebitis, characterized by blood clots near the surface of the skin.
The disease also increases the risk of heart attack, the agency said Thursday in a news release.
Jakafi has been approved for polycythemia vera patients who cannot tolerate or have an inadequate response to other drugs. In clinical studies involving 222 people, Jakafi’s most common side effects included low counts of red blood cells and blood platelets, dizziness, constipation and shingles.
The drug was first approved in 2011 to treat another bone marrow disorder, myelofibrosis.
Jakafi is marketed by Incyte Corp., based in Wilmington, Del.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.